Eli Lilly and Company

Karin Briner

Matthew Joseph Fisher

Roger Ryan Rothhaar

Jeffrey Thomas Mullaney

Matthew Robert Reinhard

Michael J Martinelli

Timothy Paul Burkholder

John Gordon Allen

Maria Angeles Martinez-Grau

Vincent Mancuso

Christopher William Doecke

Chaoyu Xie

Joseph P Burkhart

Yanping Xu

Andrew Caerwyn Williams

Frantz Victor

Christopher Stanley Galka

Shawn Christopher Miller

Deyi Zhang

Michael Philip Mazanetz

William Harlan Gritton

Paul Leslie Ornstein

Leonard Larry Winneroski, Jr

Michael J Rodriguez

Yao-Chang Xu

Qing Shi

Natalia Pokrovskaia

Timothy Ivo Richardson

Steven Lee Kuklish

Zhipei Wu

Michael Wade Tidwell

Richard C Hoying

Ryan Thomas Backer

Anne Marie Camp

Brian Eugene Cunningham

Steven Armen Boyd

Julie M Miyashiro

Cynthia Darshini Jesudason

Larry W Hertel

Dennis C Thompson

Daniel Timothy Kohlman

Sidney Xi Liang

Mark Louis Heiman

Ajay Singh

Freddie Craig Stevens

Michael Philip Cohen

Richard Edmund Rathmell

Ana Isabel Mateo Herranz

Manuel Javier Cases-Thomas

John Philip Mayer

Selma Sapmaz

Cristina Garcia-Paredes

Sarah Lynne Hellman

Ivan Collado Caño

Jikesh Arvind Shah

Oscar De Frutos Garcia

David Lloyd Garver Nelson

Christopher Stephen Siedem

Wai-Man Lee

Arundhati S Deo

Christopher Kelly Biggers

Alan Cornell

Michael John Rodriguez

Richard Gerard Conway

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where:

[object Object]

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where Ris &#x2014;C&#x2261;C&#x2014;R, &#x2014;CH&#x2550;CRR, or &#x2014;(C-C)alkyl-Aroptionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification. 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N&#x2014;R&#x2033;R* where R6 is &#x2014;(CrC3)alkyl-S&#x2014;(C0-C3)alkyl-R10, &#x2014;(C1-C3)alkyl-NR11R12, &#x2014;(CrC3)alkyl-O&#x2014;R13. and other substituents are as defined in the specification. 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: Ris selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification. 

The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

Melanocortin receptor agonists

The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

Piperazine- and piperidine-derivatives as melanocortin receptor agonists

The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 

Substituted piperidines/piperazines as melanocortin receptor agonists

The present invention provides serotonergic aminoalkylbenzofurans of Formula (I): where R, R, R, R, R, R', R, R&#x2032;, and Rare as described in the specification. 

Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists

The present invention provides serotonergic benzofurylpiperazines of Formula I:where:

Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists

The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and Rare as described in the specification.

Serotonergic benzofurans

Benzofurylpiperazine serotonin agonists

Growing community of inventors

Indianapolis, IN, United States of America

Karin Briner